At the end of July, Atellas, the manufacturer of the drug Asamax, confirmed that it was ending production of the drug. The agent will not be reimbursed from the new year. This has caused concern among patients with inflammatory bowel disease for whom the drug is used. - There is no need to sow unnecessary panic. We have other drugs with mesalazine (the active ingredient in the drug Asamax)," Krzysztof Hadrian of the Department of Gastroenterology and Internal Medicine at UCK WUM said at the Inflammatory Bowel Diseases Education Day.
- The company said that due to business and strategic considerations, it will ensure the availability of Asamax only until the end of 2024 at a reduced, refundable price. After that, availability will depend only on inventory," Krzysztof Hadrian explaine...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
